235 related articles for article (PubMed ID: 36125673)
1. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
Hamidianjahromi A; Tritos NA
Rev Endocr Metab Disord; 2022 Oct; 23(5):1089-1099. PubMed ID: 36125673
[TBL] [Abstract][Full Text] [Related]
2. MANAGEMENT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry?
Barake M; Klibanski A; Tritos NA
Eur J Endocrinol; 2018 Dec; 179(6):R287-R296. PubMed ID: 30324793
[TBL] [Abstract][Full Text] [Related]
3. Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors.
De Sousa SMC; Baranoff J; Rushworth RL; Butler J; Sorbello J; Vorster J; Thompson T; McCormack AI; Inder WJ; Torpy DJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31580439
[TBL] [Abstract][Full Text] [Related]
4. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.
Beccuti G; Guaraldi F; Natta G; Cambria V; Prencipe N; Cicolin A; Montanaro E; Lopiano L; Ghigo E; Zibetti M; Grottoli S
J Endocrinol Invest; 2021 Aug; 44(8):1699-1706. PubMed ID: 33314003
[TBL] [Abstract][Full Text] [Related]
5. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
Almalki MH; Alsuraikh MA; Almalki E; Aziz F; Almazrouei R; AlDahmani KM; Alshahrani F; Alaqeel M; Mahzari M; Ekhzaimy A
Pituitary; 2024 Apr; 27(2):197-203. PubMed ID: 38345719
[TBL] [Abstract][Full Text] [Related]
6. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.
Bancos I; Nannenga MR; Bostwick JM; Silber MH; Erickson D; Nippoldt TB
Clin Endocrinol (Oxf); 2014 Jun; 80(6):863-8. PubMed ID: 24274365
[TBL] [Abstract][Full Text] [Related]
7. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
Ioachimescu AG; Fleseriu M; Hoffman AR; Vaughan Iii TB; Katznelson L
Eur J Endocrinol; 2019 Jan; 180(1):31-40. PubMed ID: 30400048
[TBL] [Abstract][Full Text] [Related]
8. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
Dogansen SC; Cikrikcili U; Oruk G; Kutbay NO; Tanrikulu S; Hekimsoy Z; Hadzalic A; Gorar S; Omma T; Mert M; Akbaba G; Yalin GY; Bayram F; Ozkan M; Yarman S
J Clin Endocrinol Metab; 2019 Jul; 104(7):2527-2534. PubMed ID: 30848825
[TBL] [Abstract][Full Text] [Related]
9. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.
Barake M; Evins AE; Stoeckel L; Pachas GN; Nachtigall LB; Miller KK; Biller BM; Tritos NA; Klibanski A
Pituitary; 2014 Apr; 17(2):150-6. PubMed ID: 23504371
[TBL] [Abstract][Full Text] [Related]
10. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas.
Martinkova J; Trejbalova L; Sasikova M; Benetin J; Valkovic P
Clin Neuropharmacol; 2011; 34(5):179-81. PubMed ID: 21738024
[TBL] [Abstract][Full Text] [Related]
11. The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study.
Ke X; Wang L; Chen M; Liu S; Yu N; Duan L; Gong F; Zhu H
BMC Endocr Disord; 2022 Apr; 22(1):97. PubMed ID: 35410236
[TBL] [Abstract][Full Text] [Related]
12. Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review.
Hamblin R; Karavitaki N
Arch Med Res; 2023 Dec; 54(8):102910. PubMed ID: 37985276
[TBL] [Abstract][Full Text] [Related]
13. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma.
Thondam SK; Alusi S; O'Driscoll K; Gilkes CE; Cuthbertson DJ; Daousi C
Clin Neuropharmacol; 2013; 36(5):170-2. PubMed ID: 24045609
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
15. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas.
Hinojosa-Amaya JM; Johnson N; González-Torres C; Varlamov EV; Yedinak CG; McCartney S; Fleseriu M
Front Endocrinol (Lausanne); 2020; 11():579606. PubMed ID: 33193096
[No Abstract] [Full Text] [Related]
16. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
17. Impulse Control Disorders with Short-term Use of Cabergoline in Macroprolactinomas: A Prospective Study with a Brief Review of Literature.
Sanjan G; Das L; Ahuja CK; Dhandapani S; Sachdeva N; Grover S; Dutta P
Neurol India; 2023; 71(1):107-112. PubMed ID: 36861582
[TBL] [Abstract][Full Text] [Related]
18. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.
Almanzar S; Zapata-Vega MI; Raya JA
Psychosomatics; 2013; 54(4):387-91. PubMed ID: 23261076
[No Abstract] [Full Text] [Related]
19. Impulse Control and Related Disorders in Parkinson's Disease.
Weintraub D; Claassen DO
Int Rev Neurobiol; 2017; 133():679-717. PubMed ID: 28802938
[TBL] [Abstract][Full Text] [Related]
20. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.
Celik E; Ozkaya HM; Poyraz BC; Saglam T; Kadioglu P
Endocrine; 2018 Dec; 62(3):692-700. PubMed ID: 30206771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
